Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
Open Access
- 1 April 2023
- Vol. 11 (4), 784
- https://doi.org/10.3390/vaccines11040784
Abstract
This study investigated the immunogenicity of, and reactogenicity to, the ChAdOx1 nCoV-19 vaccine according to pre-existing adenovirus immunity. Individuals scheduled for COVID-19 vaccination were prospectively enrolled in a tertiary hospital with 2400 beds from March 2020 onwards. Pre-existing adenovirus immunity data was obtained before ChAdOx1 nCoV-19 vaccination. A total of 68 adult patients administered two doses of the ChAdOx1 nCoV-19 vaccine were enrolled. Pre-existing adenovirus immunity was identified in 49 patients (72.1%), but not in the remaining 19 patients (27.9%). The geometric mean titer of S-specific IgG antibodies was statistically higher in individuals without pre-existing adenovirus immunity at several time points: before the second ChAdOx1 nCoV-19 dose (56.4 (36.6–125.0) vs. 51.0 (17.9–122.3), p = 0.024), 2–3 weeks after the second ChAdOx1 nCoV-19 dose (629.5 (451.5–926.5) vs. 555.0 (287.3–926.0), p = 0.049), and 3 months after the second ChAdOx1 nCoV-19 dose (274.5 (160.5–655.3) vs. 176.0 (94.3–255.3), p = 0.033). In the absence of pre-existing adenovirus immunity, systemic events were observed with higher frequency, especially chills (73.7% vs. 31.9%, p = 0.002). In conclusion, individuals without pre-existing adenovirus immunity showed a higher immune response to ChAdOx1 nCoV-19 vaccination and a higher frequency of reactogenicity to ChAdOx1 nCoV-19 vaccination was observed.Funding Information
- Korea National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency (2021-ER1902–00, 2021-ER2601-00)
- Institutes of Science and Technology
This publication has 36 references indexed in Scilit:
- Merck Ad5/HIV induces broad innate immune activation that predicts CD8 + T-cell responses but is attenuated by preexisting Ad5 immunityProceedings of the National Academy of Sciences of the United States of America, 2012
- Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectorsExpert Opinion on Biological Therapy, 2009
- New Insights on Adenovirus as Vaccine VectorsMolecular Therapy, 2009
- The influence of innate and pre‐existing immunity on adenovirus therapyJournal of Cellular Biochemistry, 2009
- Antiviral Antibodies Target Adenovirus to Phagolysosomes and Amplify the Innate Immune ResponseThe Journal of Immunology, 2009
- Characterization of culture-positive adenovirus serotypes from respiratory specimens in Toronto, Ontario, Canada: September 2007–June 2008Virology Journal, 2009
- Safety and Immunogenicity of Adenovirus-Vectored Near-Consensus HIV Type 1 Clade BgagVaccines in Healthy AdultsAIDS Research and Human Retroviruses, 2009
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and DJournal of Virology, 2007
- Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan AfricaEmerging Infectious Diseases, 2006